Health TrialsbyHealthPanel

FDG-PET in the Diagnosis of Autoimmune Encephalitis

ConditionAutoimmune Encephalitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Milano Bicocca

About this trial

The goal of this retrospective observational study is to compare brain fluorodeoxyglucose-positron emission tomography (FDG-PET) of patients with autoimmune encephalitis, normal controls and patients with Alzheimer's disease (AD). The main question it aims to answer is:

•is there a specific pattern of brain metabolism in patients with autoimmune encephalitis Participants data and images will be retrospectively collected from hospital records, and FDG-PET images will be analyzed by means of statistical parametric mapping (SPM). Controls will be selected from validated public databases.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of autoimmune encephalitis according to clinical criteria

Brain magnetic resonance imaging performed between clinical presentation and treatment

Cerebrospinal fluid analysis performed between clinical presentation and treatment

Brain FDG-PET performed between clinical presentation and treatment

Disqualifiers

Refusal to give consent for the study

Trial population

Patients with autoimmune encephalitis admitted to the recruiting centers

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • FDG-PET

    Diagnostic test

    Brain FDG-PET

Treatment groups

90 Participants
are divided into 1 treatment group
Group A: Autoimmune Encephalitis patients1 intervention

Trial outcomes

Primary outcomes

1

SPM analysis of brain metabolic pattern

Pattern of brain metabolism in patients with autoimmune encephalitis compared with healthy controls and patients with Alzheimer's disease, drawn from validated published databases

Time frame
up to 6 months

Secondary outcomes

1

Sensitivity of basal ganglia hypermetabolism

Sensitivity of basal ganglia hypermetabolism for the diagnosis of autoimmune encephalitis

Time frame
up to 6 months
2

Diagnostic delay

Comparison of diagnostic delay with and without FDG-PET

Time frame
up to 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Milano Bicocca

Lead sponsor

Source ClinicalTrials.gov
Apply now